SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Art Vandelay AIA who wrote (2767)5/14/1999 5:05:00 PM
From: Biomaven   of 10280
 
One final point, I spoke with SEPR and they confirmed that they have been and will continue to be paying for 100% of the Nori development. Only upon exercising of the option was JNJ to reimburse them.

I don't understand this, because their agreement stated the following:


6. COMPENSATION PAYABLE TO SEPRACOR

6.1 Pre-Option Clinical Testing Expenses.

(a) For the rights and options granted hereunder, Janssen
shall pay Sepracor [**] of the expenses incurred by Sepracor in conducting and
analyzing the results of the Pre-Option Clinical Testing.

(b) Sepracor shall submit a statement to Janssen on a monthly
basis at the end of each month of the Johnson & Johnson universal calendar as to
the aforesaid expenses in Section 6.1(a) actually incurred by Sepracor, together
with an invoice for [**] of such expenses. Janssen shall pay such invoices
within thirty (30) days of the end of the calendar month during which the
invoice was issued to Janssen.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News